Thimm, Andreas http://orcid.org/0000-0002-7806-9919
Carpinteiro, Alexander
Oubari, Sara
Papathanasiou, Maria
Kessler, Lukas
Rischpler, Christoph
Malik, Rayaz Ahmed
Herrmann, Ken
Reinhardt, Hans Christian
Rassaf, Tienush
Kleinschnitz, Christoph
Hagenacker, Tim
Stettner, Mark
Funding for this research was provided by:
Universitätsmedizin Essen Clinician Scientist Academy (FU 356/12-2)
Universitätsklinikum Essen
Article History
Received: 10 January 2023
Revised: 21 March 2023
Accepted: 25 March 2023
First Online: 4 April 2023
Declarations
:
: A.T. received speaker honoraria from Alnylam and Sobi. H.C.R. received consulting and lecture fees from Abbvie, AstraZeneca, Vertex, Roche, Novartis and Merck. H.C.R. received research funding from Gilead Pharmaceuticals. H.C.R. is a co-founder of CDL Therapeutics GmbH. The other authors report no competing interests.
: The study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments and was approved by the ethics committee of the University Duisburg-Essen (approval number 20-9583-BO) and the North Manchester Ethics committee (control group).
: Informed consent was obtained from all individual participants included in the study.
: All participants gave their written informed consent to publishing their data.